Primer: JW Therapeutics (2126 HK) - Aug 2026
JW Therapeutics is a clinical-stage cell therapy company at the forefront of China's nascent but rapidly growing CAR-T market, with its lead...
87 Views
𝛼SK or SearchENTITY
JW Therapeutics (2126 HK)
JW Therapeutics (2126 HK)
41
Analysis
Health Care • China
JW Therapeutics is a clinical-stage cell therapy company focused on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product is Carteyva (relmacabtagene autoleucel), an autologous anti-CD19 CAR-T therapy. The company is headquartered in Shanghai, China, and was founded in 2016.
morex